Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Captainblkon Jan 09, 2020 1:28pm

74 Views

Post# 30535323

RE:RE:RE:RE:RE:RE:A short history of what we know so far in relation to the

Wayned52 wrote: So you can put out a misunderstood nr but you can`t clear it up or answer any emails .

Well If you were working on a 5 BILLION dollar plus deal(a number that's being thrown around) you'd probably want to play your cards close to your chest, and be sure to cross your t's and dot your I's so as to not get in trouble with any ruling bodies

Bullboard Posts

Changing Europe’s dependency on HREE from China